Biliary Tract Cancer Pipeline Outlook, FDA Approvals, Clinical Trials And Companies 2024 (Updated)

(MENAFN- GetNews) DelveInsight's,
“Biliary Tract Cancers Pipeline Insight 2024”
report provides comprehensive insights about
80+ companies and 80+ pipeline drugs
in the Biliary Tract Cancers Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Biliary Tract Cancer Pipeline Report

• DelveInsight's Biliary Tract Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for treatment.
• The leading Biliary Tract Cancer Companies working in the market include Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others.
• Promising Biliary Tract Cancer Therapies in the various stages of development include Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others.
• May 2024:- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins- Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers. The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
• May 2024:- Eli Lilly and Company- A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors. The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
• April 2024- AstraZeneca- A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE). This study involves assessing the safety and efficacy of durvalumab in combination with different gemcitabine-based chemotherapy regimens as first line therapy for aBTC. The target population of interest in this study is participants with aBTC who are ≥ 18 years of age and above legal age per local regulations with WHO/ECOG PS of 0 to 2 at enrolment and who are not eligible for locoregional therapy.

Request a sample and discover the recent advances in Biliary Tract Cancer @ Biliary Tract Cancer Pipeline Outlook Report

Biliary Tract Cancer Overview

Biliary tract cancer is a cancer that forms in the cells of the bile ducts, gallbladder or ampulla of Vater. Cancer of the bile ducts is called cholangiocarcinoma and is classified depending on which part of the bile duct the cancer develops into intrahepatic (affects bile ducts within the liver), hilar (occurs at the junction of the left and right hepatic ducts) and extrahepatic (affects the common bile duct outside the liver) sharing different genetic, risk factors and clinical presentation.

Biliary tract cancer: Emerging Drugs

• MRG 002: Miracogen
• Disitamab vedotin: Yantai Rongchang Pharmaceutical
• Envafolimab: Alphamab Oncology
• DKN-01: Leap Therapeutics

Learn more about Biliary Tract Cancer in clinical trials @ Biliary Tract Cancer Drugs

Biliary Tract Cancer Therapeutics Assessment

There are approx. 80+ Biliary Tract Cancer companies are developing Biliary Tract Cancer therapies. The Biliary Tract Cancer companies with their Biliary Tract Cancer drug candidates in the most advanced stage, i.e. phase II/III include, SMT Bio Co., Ltd.

DelveInsight's Biliary Tract Cancer Pipeline Report covers around
80+ products
under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Biliary Tract Cancer in development @ Biliary Tract Cancer Clinical Trials

Biliary Tract Cancer Companies

Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others

The Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Biliary Tract Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

To learn more about Biliary Tract Cancer, visit @ Biliary Tract Cancer Segmentation

Scope of the Biliary Tract Cancer Pipeline Report

• Coverage- Global
• Biliary Tract Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Biliary Tract Cancer Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others
• Biliary Tract Cancer Therapies- Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others.

Table of Content